argenx Posts $1.5B Q2 Sales, 60% Growth; Key Pipeline Readouts on Track

summarizeSummary

argenx reported Q2 2026 VYVGART sales of $1.5B (+60% YoY), H1 profit of $838M, and $5.2B in cash. The gMG label expansion to all serotypes launched, and pivotal myositis and MMN readouts are on track for 2H26.

check_boxKey Events · Earnings and Guidance · ARGX

• Q2 Sales Surge 60% to $1.5B

  Global VYVGART product net sales reached $1.5 billion in Q2 2026, a 60% year-over-year increase driven by U.S. demand and the seronegative gMG label expansion launch.

• H1 Profit Hits $838M

  Half-year operating profit rose to $887 million, with net profit of $838 million ($13.47 basic EPS), as revenue growth outpaced a 37% increase in operating expenses.

• Cash Pile Grows to $5.2B

  Cash, equivalents and current financial assets totaled $5.2 billion at June 30, 2026, up from $4.4 billion at year-end 2025, providing ample runway for pipeline investment.

• Pivotal Myositis Readout in 3Q26

  Topline results from the registrational ALKIVIA study in autoimmune myositis are expected in the third quarter of 2026, a major catalyst for VYVGART expansion into rheumatology.

auto_awesomeAnalysis · ARGX · Life Sciences

argenx delivered a standout quarter with $1.5 billion in global VYVGART sales, up 60% year-over-year and 17% sequentially, driving half-year profit to $838 million. The company launched its expanded gMG label to all serotypes, unlocking a new patient population, and confirmed that pivotal readouts for myositis (3Q26) and empasiprubart in MMN (4Q26) remain on schedule — events that could transform the pipeline into a multi-franchise immunology powerhouse. With $5.2 billion in cash and a rapidly scaling commercial engine, argenx is funding its Vision 2030 ambitions from operations, a rare position in biotech.